



Trust Fact Sheet

Ordinary Shares

Share Price	366.00p
NAV per share	379.47p
Premium	-
Discount	-3.55%
Capital	99,365,000 shares of 25p*

*Excluding Ordinary shares held in treasury

Assets & Gearing¹

Total Gross Assets	£377.0m
Total Net Assets	£377.0m
AIC Gearing Ratio	5.00%
AIC Net Cash Ratio	n/a

Fees²

Management	£0 - £500m: 0.70% Above 500m: 0.65%
Ongoing Charges (incl. management fees)	0.90%

Historic Yield (%) **0.60**

Dividends (pence per share)³

February 2026 (Paid)	1.00
August 2025 (Paid)	1.20
February 2025 (Paid)	1.20
August 2024 (Paid)	1.20

Fund Managers



James Douglas

Fund Manager

James has worked closely with the Trust since joining Polar Capital in 2015, becoming co-manager in August 2019 and has 24 years of healthcare experience.



Gareth Powell

Head of Healthcare

Gareth co-founded the Healthcare team in 2007, has 26 years of industry experience and has been working as co-manager on the Trust since August 2019.

Fund Ratings and Awards



Ratings are not a recommendation.

Trust Profile

Investment Objective

The Company's investment objective is to generate capital growth by investing in a global portfolio of healthcare stocks.

Investment Policy


The Company seeks to achieve this objective by investing in a diversified global portfolio consisting primarily of listed equities issued by healthcare companies involved in pharmaceuticals, medical services, medical devices and biotechnology. The portfolio is expected to be diversified by factors such as geography, industry sub-sector and investment size with a multi-capitalisation approach.

Key Facts

- An investment trust seeking capital growth across the healthcare sector
- Invests across a diverse and rapidly advancing industry
- Portfolio of typically 25-60 stocks
- High conviction and actively managed

Performance

Performance Since Launch (%)



	1m	3m	YTD	1yr	3yrs	Since Launch ⁶
Ordinary Share Price (TR)	-12.23	-12.86	-12.86	11.24	17.66	358.79
NAV per Share (TR)	-8.20	-8.64	-8.64	8.00	13.72	409.81
MSCI ACWI / Healthcare TR	-6.41	-2.52	-2.52	2.19	9.45	453.66

Discrete Annual Performance (%)

	Financial YTD	31.03.25	28.03.24	31.03.23	31.03.22	31.03.21
Ordinary Share Price (TR)	3.34	11.24	-11.17	19.07	6.35	24.85
NAV (undiluted per Share)	2.94	8.00	-11.50	18.98	2.61	21.19
MSCI ACWI / Healthcare TR	7.19	2.19	-3.00	10.42	2.21	17.90

Performance relates to past returns and is not a reliable indicator of future returns.

Source: Bloomberg & HSBC Securities Services (UK) Limited, percentage growth, Net of Fees in GBP terms.

1. Gearing calculations are exclusive of current year revenue/loss.

2. Management fees are charged 80% to capital and 20% to revenue. The management fee is based on the lower of the Market Capitalisation and Adjusted NAV. Ongoing charges (OCR) are calculated at the latest published year end date. Ongoing Charges are the total operating expenses, including management fees of the Company expressed as a percentage of the average daily net asset value during the year. The OCR shows the annual percentage reduction in the net asset value as a result of the costs of running the Company. The OCR for the year to 30 September 2025 was 0.90%. The figures are current estimates and may change in the future. Please see the Annual Report and Financial Statements for further information about the calculation of fees.

3. The Company pays two dividends a year.

4. The ordinary share price has been adjusted for dividends paid in the period in GBP and reinvested at the ex-dividend date.

5. The NAV per share is adjusted to show dividends reinvested on the payment date in ordinary shares at their Net Asset Value; to remove the dilution of the exercise of the subscription rights and, to remove any effects from any issuance or repurchase of ordinary shares. This is the metric used by the Company when assessing the investment manager's performance.

6. The Company was restructured on 20 June 2017. The Company carried out a tender offer in response to proposals, to extend the Company's life indefinitely subject to regular tender offers, that were put to shareholders on 22 October 2025 and passed at a General Meeting on 27 November 2025.

Risk Warning Your capital is at risk. You may not get back the full amount you invested. Please note the Risks and Important information at the end of this document, and the Investment Policy and full Risk Warnings set out in the Prospectus, Annual Report and/or Investor Disclosure Document.

Discount Warning The shares of investment trusts may trade at a discount or a premium to Net Asset Value for a variety of reasons including market sentiment and market conditions. On a sale you could realise less than the Net Asset Value and less than you initially invested.

FE Alpha Manager Ratings do not constitute investment advice offered by FE and should not be used as the sole basis for making any investment decision. © 2023 FE. All rights reserved.

Source & Copyright: CITYWIRE. Gareth Powell & James Douglas have been awarded a Plus rating by Citywire for their 3 year risk-adjusted performance for the period 27/02/2023 - 27/02/2026.

Portfolio Exposure

As at 31 March 2026

Top 10 Positions (%)

Eli Lilly & Co	8.6
AstraZeneca	6.4
Roche Holding AG	5.2
Thermo Fisher Scientific	4.9
CVS Health Corp	4.7
Teva Pharmaceutical Industries	4.6
Cigna Corp	4.0
Fresenius SE & Co NPV	3.4
Novo Nordisk A/S	3.2
UCB	2.9
Total	47.8

Total Number of Positions 40

Active Share 79.66%

Market Capitalisation Exposure (%)

Mega Cap (>US\$100bn)	28.3
Large Cap (US\$10bn - 100bn)	48.3
Mid Cap (US\$5 bn - 10 bn)	13.1
Small Cap (<US\$5 bn)	15.2
Cash	-4.9

Trust Characteristics

Launch Date	15 June 2010
Year End	30 September
Results Announced	December/January
Next AGM	February/March
Listed	London Stock Exchange
Trust Term	No fixed life; 5 yearly tender offers
Next Tender Offer	By 31 March 2031

Benchmark

MSCI All Country World Index / Healthcare (Sterling)


Codes

Ordinary Shares

ISIN	GB00B6832P16
SEDOL	B6832P1
London Stock Exchange	PCGH


Sector Exposure (%)

	Fund	Relative
Pharmaceuticals	43.5	-3.8
Biotechnology	24.0	7.1
Healthcare Services	15.2	12.2
Life Sciences Tools & Services	8.6	1.3
Healthcare Equipment	5.3	-8.3
Healthcare Supplies	2.8	0.3
Managed Healthcare	2.5	-1.9
Healthcare Distributors	2.1	-0.7
Healthcare Technology	0.8	0.4
Healthcare Facilities	0.0	-1.7
Cash	-4.9	-4.9



Geographic Exposure - Top Overweights & Underweights Relative to Index (%)

	Fund	Relative
United States	48.7	-18.3
United Kingdom	9.3	3.4
Germany	8.1	6.7
Denmark	7.1	5.3
Switzerland	5.2	-4.1
Israel	4.6	4.1
Ireland	3.5	2.1
Japan	3.2	-0.7
Belgium	2.9	2.3
India	2.7	1.6
Other	9.8	2.4
Cash	-4.9	-4.9



The column headed "Fund" refers to the percentage of the Fund's assets invested in each sector. The column headed "Relative" refers to the extent to which the Fund is overweight or underweight in each sector compared (relative) to the index.

The entire investment portfolio is published in the annual and half year report as well as being announced to the London Stock Exchange on a quarterly basis.

Note: Totals may not sum due to rounding. It should not be assumed that recommendations made in future will be profitable or will equal performance of the securities in this document. A list of all recommendations made within the immediately preceding 12 months is available upon request.

Investing in the Trust and Shareholder Information

Market Purchases

The ordinary shares are listed and traded on the London Stock Exchange. Investors may purchase shares through their stockbroker, bank or other financial intermediary.

Share Dealing Services

Details of the different ways of dealing in the company's shares are given on the website. Equiniti, the company's registrars provide an internet share sale service.

Telephone 0800 876 6889

Online www.shareview.co.uk

Corporate Contacts

Registered Office and Website
16 Palace Street, London SW1E 5JD
www.polarcapitalglobalhealthcaretrust.co.uk

Custodian
HSBC Plc is the Depositary and provides global custody of all the company's investments.

Registrar
Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA
www.shareview.co.uk

Fund Managers' Comments

Market and sector review

March was a challenging month for equity markets globally on the back of heightened geopolitical tensions which resulted in a spike in oil prices and a consequent increase in bond yields. Unsurprisingly, the energy sector performed especially well while sectors that historically correlate negatively to sudden rises in interest rates, such as consumer staples, industrials and healthcare, struggled.

Geographically, emerging markets and European stocks lagged their US counterparts, partly due to a stronger dollar and the view that the US economy is more self-sufficient in terms of energy requirements. As hinted above, the healthcare sector underperformed the broader market with pharmaceuticals, biotechnology, life sciences tools and services posting less negative returns relative to healthcare distributors, facilities, equipment and supplies.

Equity market performance during the month was shaped largely by developments in the Middle East. Following the 28 February US/Israeli strikes on Iran, the conflict continued through March and shipping flows through the Strait of Hormuz fell sharply, severely disrupting global energy markets. Brent crude rose by more than 60% over the month, while bond yields moved materially higher as investors reassessed the inflation outlook.

In response, many looked back to earlier oil shocks, including the 1973 Arab embargo, the 1979 Iranian revolution, the 1990 Gulf War and the 2022 Russia/Ukraine conflict, to see which playbook central banks might adopt this time. It became increasingly clear that the easing narrative which began to take hold last year is no longer intact. On 18 March, the Federal Reserve left interest rates unchanged while adopting a more hawkish tone as energy-driven inflation risks intensified. The following day, the ECB also stayed on hold, warning that the conflict had introduced both upside risks to inflation and downside risks to growth. For now, with no visibility on how long the conflict will persist or how quickly normal shipping can resume through Hormuz, central banks appear to be in risk-management mode, trying to balance inflation control against the danger of placing further strain on an already slowing global economy and softening labour market.

Against that backdrop, healthcare's underperformance relative to the broader market may seem counterintuitive, given its reputation as a defensive sector. In practice, however, investors often treat healthcare as a bond proxy. When oil prices rise sharply and inflation expectations move higher, bond yields tend to increase which can weigh on both bond prices and other yield-sensitive sectors such as healthcare. That said, if the current inflation shock proves predominantly supply-driven and begins to undermine growth, prompting more stagflationary concerns, sentiment could shift. In that environment, healthcare's resilient earnings profile and relative defensiveness may once again become more attractive to investors.

Fund performance

The Company's net asset value (NAV) declined by 8.2% in March, behind the benchmark, the MSCI All Country World Net Total Return Health Care Index, which was down 6.4% for the month (both figures in sterling terms).

Positive relative contributors relative to the benchmark in March were BridgeBio Pharma, Cytokinetics and Nuvalent.

BridgeBio Pharma performed strongly, thanks to a combination of good commercial momentum as shown in its Q4 earnings report and positive data from one of its pipeline drugs, BBP-418, a potential first-in-class treatment for limb-girdle muscular dystrophy – a rare genetic disease that causes muscle weakening and wasting. Additionally, there were

favourable legal developments which meant generic competition from a competitive asset might be delayed

Cytokinetics and Nuvalent both performed well without delivering any thesis-changing news but were caught up in the positive sentiment driven by encouraging pipeline developments and M&A.

Negative relative contributors included Centene, Johnson & Johnson and Chugai Pharmaceutical (Chugai).

At a broker conference, US managed care company Centene reiterated full-year 2026 guidance, but the weakness was caused by a comment that the company is seeing higher utilisation patterns in specialty pharmacy, an observation isolated to the company's silver-tier plans.

The Fund had no exposure to Johnson & Johnson, a stock that continues to re-rate given its defensive qualities. Chugai's disappointing performance was driven by the company's decision to discontinue the development of a pipeline asset for two rare muscular disorders, spinal muscular atrophy and facioscapulohumeral muscular dystrophy.

We initiated a position in Xenon Pharmaceuticals, a US-based biotechnology company, following the release of positive top-line data for its lead asset for the treatment of focal onset seizures, the most common type of epilepsy seizure.

Outlook

Geopolitical unrest in the Middle East and the inflationary implications of a spike in energy costs has created a great deal of uncertainty for investors. Importantly, however, that uncertainty has created exciting investment opportunities, with current valuations disconnected from the strong fundamentals. The innovation cycle remains very strong and M&A is picking up, with several multi-billion-dollar deals announced since the turn of the year.

The demand for healthcare products and services continues to be robust, with emerging markets especially buoyant. Last, but not least, policy fears in the US appear to be easing which is a significant positive that should not be overlooked.

James Douglas & Gareth Powell

7 April 2026

Performance relates to past returns and is not a reliable indicator of future returns.

It should not be assumed that recommendations made in future will be profitable or will equal performance of the securities in this document. A list of all recommendations made within the immediately preceding 12 months is available upon request.

Risks

- Investors' capital is at risk and there is no guarantee the Company will achieve its objective.
- Past performance is not a reliable guide to future performance.
- The value of investments may go down as well as up.
- Investors might get back less than they originally invested.
- The value of an investment's assets may be affected by a variety of uncertainties such as (but not limited to): (i) international political developments; (ii) market sentiment; and (iii) economic conditions.
- The shares of the Company may trade at a discount or a premium to Net Asset Value.
- The Company may use derivatives which carry the risk of reduced liquidity, substantial loss and increased volatility in adverse market conditions.
- The Company invests in assets denominated in currencies other than the Company's base currency and changes in exchange rates may have a negative impact on the value of the Company's investments.
- The Company invests in a concentrated number of companies based in one sector. This focused strategy can lead to significant losses. The Company may be less diversified than other investment companies.
- The Company may invest in emerging markets where there is a greater risk of volatility than developed economies, for example due to political and economic uncertainties and restrictions on foreign investment. Emerging markets are typically less liquid than developed economies which may result in large price movements to the Company.

Glossary

Active Share, a measure of how actively a portfolio is managed, is the percentage of the portfolio that differs from its benchmark. It is calculated by deducting from 100 the percentage of the portfolio that overlaps with the benchmark. An active share of 100 indicates no overlap with the benchmark and an active share of zero indicates a portfolio that tracks the benchmark.

Alpha is the excess return on an investment in the Company compared to the benchmark and can be used as a measure of performance, where the benchmark is considered to represent the market's movement as a whole.

Derivatives are instruments whose value is linked to another investment, or to the performance of a stock exchange or to some other variable factor, such as interest rates.

Discount is where the share price of an investment company is lower than the net asset value per share.

Discrete Performance is the percentage performance of an investment over specific, defined time periods.

Emerging markets are countries that are progressing toward becoming advanced, usually shown by some development in financial markets, the existence of some form of stock exchange and a regulatory body.

Gearing is all external borrowings of the Company and any subsidiaries.

Management Fee is the entitlement of the Investment Manager to an annual management fee. Please see the Explanation of Fee Arrangements available on the Company's

website for further information, found at: <https://www.polarcapitalglobalhealthcaretrust.co.uk/Key-Information/#/Overview>

"NAV" or "Net Asset Value" has the value of all assets of the Company less liabilities to creditors (including provisions for such liabilities) determined in accordance with the Company's accounting policies, applicable accounting standards and the Company's constitution.

Ongoing Charges are the measure of what it costs to run the Company, including the Management Fee and other operating costs; these costs are not passed on to investors in the price they pay for the shares of the Company.

Premium is where the share price of an investment company is higher than the net asset value per share.

For a complete glossary of investment terms, please refer to the Trust's website: <https://www.polarcapitalglobalhealthcaretrust.co.uk/Glossary/>

Important Information

Not an offer to buy or sell This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security, and under no circumstances is it to be construed as a prospectus or an advertisement. This document does not constitute, and may not be used for the purposes of, an offer of the securities of, or any interests in, the Company by any person in any jurisdiction in which such offer or invitation is not authorised.

Information subject to change Any opinions expressed in this document may change.

Not Investment Advice This document does not contain information material to the investment objectives or financial needs of the recipient. This document is not advice on legal, taxation or investment matters. Prospective investors must rely on their own examination of the consequences of an investment in the Company. Investors are advised to consult their own professional advisors concerning the investment.

No reliance No reliance should be placed upon the contents of this document by any person for any purposes whatsoever. None of the Company, the Investment Manager or any of their respective affiliates accepts any responsibility for providing any investor with access to additional information, for revising or for correcting any inaccuracy in this document.

Performance and Holdings All data is as at the document date unless indicated otherwise. Company holdings and performance are likely

to have changed since the report date. Company information is provided by the Investment Manager.

Benchmark The Company is actively managed and uses the MSCI All Country World Index/Healthcare as a performance target. The benchmark is considered to be representative of the investment universe in which the Company invests. The performance of the Company is likely to differ from the performance of the benchmark as the holdings, weightings and asset allocation will be different. Investors should carefully consider these differences when making comparisons. Further information about the benchmark can be found at: www.msibarra.com

Third-party Data Some information contained in this document has been obtained from third party sources and has not been independently verified. Neither the Company nor any other party involved in compiling, computing or creating the data makes any warranties or representations with respect to such data, and all such parties expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any data contained within this document.

Country Specific Disclaimers

United States The information contained within this document does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which such an offer or solicitation

would be unlawful. The Company has not been and will not be registered under the United States Investment Company Act of 1940, as amended (the "Investment Company Act") and, as such, the holders of its shares will not be entitled to the benefits of the Investment Company Act. In addition, the offer and sale of the Securities have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"). No Securities may be offered or sold or otherwise transacted within the United States or to, or for the account or benefit of U.S. Persons (as defined in Regulation S of the Securities Act). In connection with the transaction referred to in this document the shares of the Company will be offered and sold only outside the United States to, and for the account or benefit of non-U.S. Persons in "offshore- transactions" within the meaning of, and in reliance on the exemption from registration provided by Regulation S under the Securities Act. No money, securities or other consideration is being solicited and, if sent in response to the information contained in this document, will not be accepted. Any failure to comply with the above restrictions may constitute a violation of such securities laws.

Further Information about the Company

Investment in the Company is an investment in the shares of the Company and not in the underlying investments of the Company. Further information about the Company and any risks can be found in the Company's Key Information Document, the Annual Report and Financial Statements and the Investor Disclosure Document which are available on the Company's website, found at: <https://www.polarcapitalglobalhealthcaretrust.co.uk>